10975 North Torrey Pines Road
About Ambrx, Inc.
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.
Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular.
At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
62 articles with Ambrx, Inc.
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May.
Ambrx Biopharma Inc., or Ambrx announced that it filed its annual report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission on April 26, 2022.
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that the company will release full year 2021 financial results on Tuesday April 26, 2022 after the close of market.
Ambrx Biopharma Inc. to Present at Oppenheimer’s 32nd Annual Healthcare Conference.
Ambrx Biopharma Inc. today announced it received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA).
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
Ambrx Biopharma Inc. today announced the first patient has been dosed in its global ACE-Breast-03 Phase 2 clinical study of ARX788 in patients with HER2-positive metastatic breast cancer.
Ambrx Biopharma Inc., or Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, announced that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will present at the 30th Annual Virtual Credit Suisse Healthcare Conference on Monday, November 8th, 2021, at 4:20 PM ET.
Ambrx today announced that NovoCodex Pharmaceuticals Ltd. presented positive interim data from the ACE-Gastric-01 Phase 1 clinical study of ARX788 for the treatment of HER2+ metastatic gastric / gastroesophageal junction (GEJ) cancer at The Chinese Society of Clinical Oncology (CSCO).
Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
Ambrx today announced the first patient has been dosed in a Phase 1, multicenter, open-label, dose-escalation, and dose expansion study to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity of ARX517 in subjects with prostate specific membrane antigen (PSMA).
Ambrx today announced the appointment of Sonja Nelson to Chief Financial Officer.
Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics, announced the pricing of its initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares, at a public offering price of $18.00 per ADS.
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
Ambrx Announces Formation and Members of Scientific Advisory Board.
Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.
Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium
- 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU - Multiple Global Phase 2/3 Trials to Begin Early 2021
Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics
Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced the successful closing of an oversubscribed US$200 million crossover financing round.
4/15/2020The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.
Ambrx Inc. and Sino Biopharmaceutical Limited announced a joint collaboration to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms.
Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates
Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed a second collaboration to develop and commercialize Ambrx's internally developed site-specific antibody drug conjugates (ADCs).